{"entity":{"id":"krt-232","kind":"drug","name":"KRT-232","aka":[],"tldr":"KRT-232 is an experimental small-molecule drug from Kartos Therapeutics in phase 2 trials for myeloproliferative neoplasms, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia, aimed at MDM2 and TP53.","summary":"KRT-232 is a small-molecule drug developed by Kartos Therapeutics. Its targets are MDM2 and TP53 (the sponsor names MDM2-p53 interaction). The sponsor states: A novel, potent and selective oral MDM2 inhibitor, referred to on the current site as navtemadlin. ClinicalTrials.gov describes the intervention as: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in myeloproliferative neoplasms, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT04502394, plans to enrol 84 participants with primary completion was scheduled for 2022-10 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of KRT-232","url":"https://clinicaltrials.gov/search?intr=KRT-232"},{"label":"Sponsor page","url":"https://www.kartosthera.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms","dlbcl","cll","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["mdm2","tp53"],"drugs":[],"companies":["kartos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05797831","nct04502394","nct03669965"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"A novel, potent and selective oral MDM2 inhibitor, referred to on the current site as navtemadlin.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/krt-232/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"target":[{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"company":[{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/"}],"trial":[{"id":"nct03669965","kind":"trial","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","route":"/trials/nct03669965/"},{"id":"nct04502394","kind":"trial","name":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","route":"/trials/nct04502394/"},{"id":"nct05797831","kind":"trial","name":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","route":"/trials/nct05797831/"}]}}